Myo-inositol in the treatment of premenstrual dysphoric disorder

Human Psychopharmacology

Volumn 26, Issue 7, 2011, Pages 526-530

  Carlomagno, Gianfranco ^a   Unfer, Vittorio ^a   Buffo, Silvia ^b   D'Ambrosio, Francesco ^c  

^a AGUNCO Obstetrics and Gynecology Centre   (Italy)

^b Casa di Cura Psichiatrica Colle Cesarano ^*  (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

myo inositol; premenstrual dysphoric disorder; selective serotonin reuptake inhibitors; soft gel capsules

Indexed keywords

INOSITOL; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POWDER; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INOSITOL; MIDDLE AGED; PREMENSTRUAL SYNDROME; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 80755187836     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1241     Document Type: Article

References (25)

1. Benjamin J, Agam G, Levine J, Bersudsky Y, Kofman O, Belmaker RH,. 1995a. Inositol treatment in psychiatry. Psychopharmacol Bull 31: 167-175.
2. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH,. 1995b. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 152: 1084-1086.
3. Borenstein J, Chiou CF, Dean B, Wong J, Wade S,. 2005. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 47: 26-33. (Pubitemid 40129010)
4. Carlomagno G, Unfer V,. 2011. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci 15: 931-936.
5. Chawla A, Swindle R, Long S, Kennedy S, Sternfeld B,. 2002. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 40: 1101-1112.
6. Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A, Pollock B, Luther J, Buttenfield J, Verfaille S, Kupfer DJ,. 2000. Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2: 47-55.
7. Cunningham J, Yonkers KA, O'brien S, Eriksson E,. 2009. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry 17: 120-137.
8. Einat H, Clenet F, Shaldubina A, Belmaker RH, Bourin M,. 2001. The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors. Behav Brain Res 118: 77-83. (Pubitemid 32037116)
9. Eriksson O, Wall A, Marteinsdottir I, Agren H, Hartvig P, Blomqvist G, Langstrom B, Naessen T,. 2006. Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Res 146: 107-116.
10. Halbreich U, Borenstein J, Pearlstein T, Kahn LS,. 2003. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28 (Suppl 3): 1-23. (Pubitemid 39658675)
11. Kaplan Z, Amir M, Swartz M, Levine J,. 1996. Inositol treatment of post-traumatic stress disorder. Anxiety 2: 51-52. (Pubitemid 126812805)
12. Lejeune F, Millan MJ,. 2000. Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors. Eur J Neurosci 12: 3265-3275.
13. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH,. 1995. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 152: 792-794.
14. Melke J, Westberg L, Landen M, Sundblad C, Eriksson O, Baghei F, Rosmond R, Eriksson E, Ekman A,. 2003. Serotonin transporter gene polymorphisms and platelet [3H] paroxetine binding in premenstrual dysphoria. Psychoneuroendocrinology 28: 446-458. (Pubitemid 36164959)
15. Nemets B, Talesnick B, Belmaker RH, Levine J,. 2002. Myo-inositol has no beneficial effect on premenstrual dysphoric disorder. World J Biol Psychiatry 3: 147-149.
16. Pearlstein T, Steiner M,. 2008. Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 33: 291-301. (Pubitemid 351977156)
17. Rosel P, Arranz B, San L, Vallejo J, Crespo JM, Urretavizcaya M, Navarro MA,. 2000. Altered 5-HT(2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims. Psychiatry Res 99: 173-181.
18. Saeed SA, Bloch RM, Antonacci DJ,. 2007. Herbal and dietary supplements for treatment of anxiety disorders. Am Fam Physician 76: 549-556. (Pubitemid 47347606)
19. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR,. 1998. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338: 209-216. (Pubitemid 28047573)
20. Steinberg S, Annable L, Young SN, Liyanage N,. 1999. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry 45: 313-320. (Pubitemid 29100037)
21. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D, Streiner D,. 1995. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 332: 1529-1534.
22. Su TP, Schmidt PJ, Danaceau M, Murphy DL, Rubinow DR,. 1997. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 82: 1220-1228. (Pubitemid 27166668)
23. Viola AU, Brandenberger G, Toussaint M, Bouhours P, Paul Macher J, Luthringer R,. 2002. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. Clin Neurophysiol 113: 429-434. (Pubitemid 34233864)
24. Yang M, Wallenstein G, Hagan M, Guo A, Chang J, Kornstein S,. 2008. Burden of premenstrual dysphoric disorder on health-related quality of life. J Womens Health (Larchmt) 17: 113-121. (Pubitemid 351197540)
25. Zukov I, Ptacek R, Raboch J, Domluvilova D, Kuzelova H, Fischer S, Kozelek P,. 2010. Premenstrual dysphoric disorderâ review of actual findings about mental disorders related to menstrual cycle and possibilities of their therapy. Prague Med Rep 111: 12-24.